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Abstract: Fibroblast growth factors (FGFs) play non-redundant autocrine/paracrine functions in
various human cancers. The Cancer Genome Atlas (TCGA) data mining indicates that high levels of
FGF and/or FGF receptor (FGFR) expression are associated with reduced overall survival, chromosome
3 monosomy and BAP1 mutation in human uveal melanoma (UM), pointing to the FGF/FGFR system
as a target for UM treatment. Here, we investigated the impact of different FGF trapping approaches
on the tumorigenic and liver metastatic activity of liver metastasis-derived murine melanoma B16-LS9
cells that, similar to human UM, are characterized by a distinctive hepatic tropism. In vitro and in vivo
experiments demonstrated that the overexpression of the natural FGF trap inhibitor long-pentraxin 3
(PTX3) inhibits the oncogenic activity of B16-LS9 cells. In addition, B16-LS9 cells showed a reduced
tumor growth and liver metastatic activity when grafted in PTX3-overexpressing transgenic mice.
The efficacy of the FGF trapping approach was confirmed by the capacity of the PTX3-derived
pan-FGF trap small molecule NSC12 to inhibit B16-LS9 cell growth in vitro, in a zebrafish embryo
orthotopic tumor model and in an experimental model of liver metastasis. Possible translational
implications for these observations were provided by the capacity of NSC12 to inhibit FGF signaling
and cell proliferation in human UM Mel285, Mel270, 92.1, and OMM2.3 cells. In addition, NSC12
caused caspase-3 activation and PARP cleavage followed by apoptotic cell death as well as β-catenin
degradation and inhibition of UM cell migration. Together, our findings indicate that FGF trapping
may represent a novel therapeutic strategy in UM.
Keywords: FGF; FGF receptors; liver metastasis; tumor grafts; uveal melanoma; zebrafish
1. Introduction
Uveal melanoma (UM) is the most common primary intraocular malignancy in adults.
Its occurrence increases with age and its incidence is more than 20 per million per year [1,2]. Current
treatments of primary UM include enucleation, radiotherapy, transpupillary thermotherapy, and local
resection, achieving a control of local tumor in up to 97% of treated cases. Anyway, the mortality rate is
high because of the frequent occurrence of metastases by hematogenous dissemination: almost 50% of
all UM patients develop metastatic disease, mainly in the liver, with a current 5-year mortality ranging
from 26% to 32% [1–3]. In the last years, a better understanding of UM biology has provided new
indications for the development of efficacious adjuvant therapies and for the treatment of the metastatic
Cancers 2019, 11, 1305; doi:10.3390/cancers11091305 www.mdpi.com/journal/cancers
Cancers 2019, 11, 1305 2 of 16
disease [4]. At present, numerous chemotherapy-, targeted therapy-, immunotherapy-, and liver
directed therapy-based clinical trials are in progress [4–6]. However, as of today, no specific systemic
treatment has been approved, indicating that novel biologically-based therapies are urgently required.
The fibroblast growth factor (FGF)/FGF receptor (FGFR) system plays a pivotal role in
different tumor types, leading to autocrine/paracrine stimulation of tumor cell proliferation and
angiogenesis [7–9]. The evidence that UM cell cultures express and secrete large quantities of FGFs
suggests that an FGF/FGFR autocrine loop of stimulation exists also in these cells [10–12], implying
the FGF/FGFR system in UM progression [13] and pointing to this pathway as a possible alternative
therapeutic target in UM.
The soluble pattern recognition receptor long pentraxin-3 (PTX3) is a member of the pentraxin
family produced locally in response to inflammatory signals [14,15]. Previous observations have
shown that PTX3 binds various FGFs, including FGF2, FGF6, FGF8b, FGF10, and FGF17, and inhibits
FGF-dependent angiogenic responses [16–18]. Accordingly, transgenic PTX3 overexpression impairs
efficaciously the activation and signaling of the FGF/FGFR system in FGF-driven tumors, thus affecting
tumor growth and metastasis [16,17,19].
Recently, the PTX3-derived small molecule NSC12 has been identified as the first orally active
pan-FGF trap able to inhibit FGFR activation and tumor growth in various FGF-dependent murine and
human tumor models [20,21]. Notably, extracellular FGF traps, including NSC12, appear to be devoid
of the toxicities associated with tyrosine kinase FGFR inhibitors [21,22], thus representing a potential
alternative option to inhibit the FGF/FGFR system in cancer. On this basis, in this work we investigated
the impact of a PTX3/NSC12-based, FGF trapping approach in the murine B16-LS9 melanoma model
and on human UM cell lines.
2. Results
2.1. The FGF/FGFR System Is Upregulated in Human Uveal Melanoma
Data mining was performed on The Cancer Genome Atlas (TCGA) UM PanCancer Atlas dataset
(http://www.cbioportal.org/study?id=uvm_tcga_pan_can_atlas_2018) to investigate the expression
of all the members of the FGFR and FGF families in a UM cohort of 80 patients. We found that
FGFRs are overexpressed in 21% of UM cases, these alterations being associated to a poor prognosis
when compared to UM cases without FGFR alterations (p = 0.023, log-rank test; median survival
equal to 31 and 52 months for cases with or without FGFR alterations, respectively) (Figure 1A,B).
Moreover, overexpression of one or more FGFs was detected in 61% of UM patients (Figure 1C). Again,
FGF overexpression appears to be associated to a reduced survival in UM patients, even though the
difference between the two groups did not reach the statistical significance (Figure 1D).
In the recent years, analysis of the genetic alterations has identified subsets of UM patients with
distinct molecular signatures [23]. Among them, UMs with loss of chromosome 3 are characterized by
a poor prognosis when compared to chromosome 3 disomic lesions. On this basis, we performed a
preliminary analysis of FGF/FGFR expression in chromosome 3 monosomic and disomic UMs of the
cohort of 80 patients present in the TCGA dataset. The results demonstrate that high-risk chromosome
3 monosomic tumors are characterized by a higher expression of FGFR1 and FGFR2, as well as of FGF5,
FGF9, FGF10, FGF12, FGF13, and FGF18 (Figure 2).
The tumor suppressor BAP1 plays a key role in UM progression and monosomy of chromosome 3
is highly associated with the loss of nuclear expression of BAP1, frequently related to loss-of-function
BAP1 mutations (see [24] and references therein). Accordingly, 13 out of the 40 chromosome 3
monosomic tumors present in the UM TCGA dataset carried a BAP1 mutation, absent in the 40 disomic
specimens. Notably, various members of the FGF/FGFR families appear to be upregulated in this
subset of BAP1 mutated tumors when compared to BAP1 wild-type UMs (Figure 2).
Together, these data point to a potential role of the FGF/FGFR axis in UM.
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Figure 1. Fibroblast growth factor receptor (FGFR) and fibroblast growth factor (FGF) overexpression
in human primary uveal melanoma (UM). Analysis of The Cancer Genome Atlas (TCGA) dataset
was performed on a cohort of 80 UM patients. (A) Pie chart showing the percentage of samples with
mRNA overexpression of the different FGFRs. (B) Overall survival of patients with or without FGFR
alterations. (C) Pie chart showing the percentage of samples with mRNA overexpression of different
members of the FGF family. Some samples showed the overexpression of more than one FGF family
member. (D) Overall survival of patients with or without FGF alterations.
2.2. PTX3 Inhibits the Tumorigenic and Metastatic Activity of Murine B16-LS9 Cells
B16-LS9 cells is a murine cell line originated from a B16-F1 liver metastasis and characterized
by a unique tropism for the hepatic tissue [25]. Even though of cutaneous origin, this cell line has
been utilized as an experimental model to investigate the mechanisms responsible for UM liver
tropism [26–28] and drug evaluation for UM treatment [29–31].
As shown in Figure 3A, B16-LS9 cells express FGF2 and its receptors FGFR1 and FGFR3.
The autocrine production of FGF2, and possibly of other FGF family members, leads to a basal
activation of FGFRs and of the downstream signaling proteins ERK1,2 and AKT (Figure 3B). Addition
of exogenous FGF2 to B16-LS9 cells causes no or only a very modest further increase in FGFR
phosphorylation and of the downstream signaling mediators phospho-AKT and phospho-ERK1,2, thus
confirming the presence of a constitutive autocrine FGF/FGFR loop of activation in these cells under
basal cell culture conditions [12].
To assess the capacity of the natural FGF trap PTX3 to suppress the constitutive activation
of the FGF/FGFR system, B16-LS9 cells were transfected with a pBABE/Puro vector harboring the
full-length human PTX3 (hPTX3) cDNA or with an empty vector. Stable hPTX3_LS9 and mock_LS9
cell populations were generated by puromycin selection. After selection, transfectants were assessed
for hPTX3 expression and secretion by RT-PCR and Western blotting, respectively (Figure 3C). The
production of hPTX3 leads to a significant inhibition of FGFR1, FGFR3, FRS2, and ERK1,2 activation
(Figure 3D) followed by a reduction of the proliferative capacity of hPTX3_LS9 cells in respect to
control non-transfected (WT_LS9) and mock_LS9 cells (Figure 3E). Accordingly, hPTX3_LS9 cells were
unable to proliferate in response to exogenous FGF2 stimulation (Figure 3F). In addition, the capacity
of hPTX3_LS9 cells to form colonies when seeded at low cell density and to repair a wounded cell
monolayer was significantly reduced in respect to control cells (Figure 3G,H).
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To assess the impact of PTX3 overexpression on the tumorigenic activity of B16-LS9 cells,
hPTX3_LS9 and mock_LS9 cells were injected subcutaneously (s.c.) in syngeneic mice. As shown
in Figure 3I, hPTX3_LS9 grafts show a reduced rate of growth when compared to mock tumors.
Next, to assess the capacity of PTX3 to affect the metastatic activity of B16-LS9 cells, WT_LS9,
mock_LS9 and hPTX3_LS9 cells were injected into the blood circulation of zebrafish embryos at
48 hours post fertilization (hpf) and the growth of micrometastases in the tail vascular plexus was
followed [32]. As shown in Figure 3J, PTX3 overexpression results in a significant reduction of the size
of micrometastases evaluated 3 days after cell injection.
Figure 2. Correlation between FGF/FGFR expression and chromosome 3 /BAP1 status in UM. Analysis
of the expression of all members of the FGFR and FGF families was performed on the cohort of 80
UM patients present in the UM TCGA dataset. FGF/FGFR genes that showed a significant differential
expression between chromosome 3 (monosomic, red symbols; disomic, open symbols) and BAP1
(mutated, blue symbols; wild-type, open symbols) status.
Cancers 2019, 11, 1305 5 of 16
Cancers 2019, 11, x FOR PEER REVIEW 5 of 16 
 
to assess the capacity of PTX3 to affect the metastatic activity of B16-LS9 cells, WT_LS9, mock_LS9 
and hPTX3_LS9 cells were injected into the blood circulation of zebrafish embryos at 48 hours post 
fertilization (hpf) and the growth of micrometastases in the tail vascular plexus was followed [32]. As 
shown in Figure 3J, PTX3 overexpression results in a significant reduction of the size of 
micrometastases evaluated 3 days after cell injection. 
 
Figure 3. Effect of long-pentraxin 3 (PTX3) overexpression on B16-LS9 cells. (A) RT-PCR analysis of 
Fgf2 and Fgfr expression in B16-LS9 cells. (B) Western blot analysis of the phosphorylation of FGFR1 
and FGFR3 and of the downstream signaling proteins ERK1/2 and AKT in B16-LS9 cells following 30 
min treatment with 30 ng/mL FGF2. (C) RT-PCR analysis of human PTX3 (hPTX3) expression in 
WT_LS9, mock_LS9, and hPTX3_LS9 cells. Inset: Western blot analysis of PTX3 protein levels in the 
extracts of the same cells. (D) Western blot analysis of the phosphorylation of FGFR1, FGFR3, FRS2, 
and ERK1/2 proteins in WT_LS9, mock_LS9, and hPTX3_LS9 cell extracts. (E) WT_LS9, mock_LS9, and 
hPTX3_LS9 cells were seeded in 48-well plates at 104 cells/well in medium containing 0.4% FBS. After 
24 h (T0), medium was changed, and cell were counted 24 and 48 h thereafter. Data are the mean ± 
SEM of three independent experiments in triplicate. (F) Cells were seeded as in (E). At T0, cells were 
treated with 30 ng/mL FGF2 and counted 24 h thereafter. Data are the mean ± SEM of three 
independent experiments in triplicate (G) WT_L69, mock_LS9, and hPTX3_LS9 cells were seeded at 
50 cells/cm2. After 10 days, cell colonies were stained with crystal violet and quantified by 
computerized image analysis. Representative images of mock_LS9 and hPTX3_LS9 cell colonies are 
shown on the right. Data are the mean ± SEM of 15 fields for each triplicate sample. (H) A mechanical 
wound was performed in WT_LS9, mock_LS9, and hPTX3_LS9 cell monolayers. After 18 h, cell 
migration at the leading edge of the wound was quantified by computerized image analysis. 
Representative images of wounded mock_LS9 and hPTX3_LS9 cell monolayers are shown on the 
right. Data are the mean ± SEM of six microscopic fields. (I) Mock_LS9 and hPTX3_LS9 cells were 
Figure 3. Effect of long-pentraxi 3 (PTX3) overe re sion on B16-LS9 cells. (A) RT-PCR analysis of
Fgf2 and Fgfr expression in B16-LS9 cells. (B) Western blot analysis of the phosphorylation of FGFR1
and FGFR3 and of the downstream signaling proteins ERK1/2 and AKT in B16-LS9 cells following
30 min treatment with 30 ng/mL FGF2. (C) RT-PCR analysis of human PTX3 (hPTX3) expression in
WT_LS9, mock_LS9, and hPTX3_LS9 cells. Inset: Western blot analysis of PTX3 protein levels in the
extracts of the same cells. (D) Western blot analysis of the phosphorylation of FGFR1, FGFR3, FRS2,
and ERK1/2 proteins in WT_LS9, mock_LS9, and hPTX3_LS9 cell extracts. (E) WT_LS9, mock_LS9,
and hPTX3_LS9 cells were seeded in 48-well plates at 104 cells/well in medium containing 0.4% FBS.
After 24 h (T0), medium was changed, and cell were counted 24 and 48 h thereafter. Data are the
mean ± SEM of three independent experiments in triplicate. (F) Cells were seeded as in (E). At T0,
cells were treated with 30 ng/mL FGF2 and counted 24 h thereafter. Data are the mean ± SEM of three
independent experiments in triplicate (G) WT_L69, mock_LS9, and hPTX3_LS9 cells were seeded at 50
cells/cm2. After 10 days, cell colonies were stained with crystal violet and quantified by computerized
image analysis. Representative images of mock_LS9 and hPTX3_LS9 cell colonies are shown on the
right. Data are the mean ± SEM of 15 fields for each triplicate sample. (H) A mechanical wound was
performed in WT_LS9, mock_LS9, and hPTX3_LS9 cell monolayers. After 18 h, cell migration at the
leading edge of the wound was quantified by computerized image analysis. Representative images of
wounded mock_LS9 and hPTX3_LS9 cell monolayers are shown on the right. Data are the mean ±
SEM of six microscopic fields. (I) Mock_LS9 and hPTX3_LS9 cells were injected subcutaneously (s.c.)
in syngeneic mice at 50,000 cells/graft and tumor growth was measured with calipers. Data are the
mean ± SEM (n = 16). (J) Red fluorescent WT_LS9, mock_LS9, and hPTX3_LS9 cells were injected into
the bloodstream of 48 hours post fertilization (hpf) zebrafish embryos (80–100 cells/embryo). During
the next 3 days, the growth of fluorescent metastases in the tail vascular plexus was quantified by
fluorescence microscopy followed by computerized image analysis. Data are the mean ± SEM of three
independent experiments (n = 20) and were normalized to metastasis areas at day 1. (K) WT_LS9
cells were injected s.c. in wild-type and transgenic TgN (Tie2-hPTX3) mice (50,000 cells/graft) and
tumor growth was measured with calipers. Data are the mean ± SEM (n = 18). (L) WT_LS9 cells were
injected into the spleen of wild-type and transgenic TgN (Tie2-hPTX3) mice (20,000 cells/graft). After 14
days, livers were harvested, and metastases were counted. Representative images of harvested livers
are shown on the right. Data are the mean ± SEM (n = 5). In (B) and (D), the right panel shows the
densitometric analysis of immunoreactive bands normalized to α-tubulin protein levels. *p < 0.05;
**p < 0.01, Student’s t-test (F,L), one-way (E,H,J) and two-way (I,K) analysis of variance.
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These observations prompted us to investigate whether also the systemic/stromal overexpression of PTX3
may exert a significant impact on the tumorigenic and metastatic activity of B16-LS9 cells. To this purpose,
WT_LS9 were grafted in syngeneic transgenic TgN (Tie2-hPTX3) mice in which PTX3 expression is driven by
the endothelial specific promoter Tie2. These animals are characterized by high levels of PTX3 protein in the
bloodstream and by its accumulation in the stroma of different organs [21]. As shown in Figure 3K, stroma
accumulation of PTX3 reduced the growth of B16-LS9 tumors grafted s.c. in transgenic mice when compared
to wild-type animals. In addition, a significant difference in liver colonization was observed between wild-type
and TgN (Tie2-hPTX3) animals following intrasplenic injection of B16-LS9 cells (Figure 3L). Together, our data
indicate that the PTX3 inhibits the tumorigenic and metastatic activity of B16-LS9 cells.
2.3. The Pan-FGF Trap NSC12 Inhibits the Tumorigenic and Metastatic Activity of Murine B16-LS9 Cells
PTX3 is a 340 kDa protein composed of eight protomers, with a complex proteinaceous structure
that hampers its pharmacological exploitation. To overcome these limitations, NMR data and
pharmacophore modeling of PTX3/FGF2 interaction were used in our laboratory to identify the
PTX3-derived small molecule NSC12 as the first orally active pan-FGF trap able to inhibit FGFR
activation and tumor growth in various FGF-dependent murine and human tumor models [20,21].
As shown in Figure 4A, treatment of B16-LS9 cells with increasing concentrations of NSC12
inhibits FGFR phosphorylation, thus affecting autocrine, FGF-mediated cell proliferation (IC50 = 2.2 µM,
Figure 4B). Accordingly, NSC12 treatment hampered the capacity of B16-LS9 cells to form colonies
when seeded at low density and to repair a wounded cell monolayer (Figure 4C,D).
Figure 4. Effect of the pan FGF-trap NSC12 on B16-LS9 cells. (A) Western blot analysis of FGFR1 and FGFR3
phosphorylation in B16-LS9 cells treated for 12 h with increasing concentrations of NSC12. The right panel
shows the densitometric analysis of immunoreactive bands normalized to GAPDH protein levels. (B) Effect
of NSC12 treatment on the proliferation of B16-LS9 cells. Viable cells were counted after 24 h of incubation
with increasing concentrations of NSC12. Data are the mean ± SEM (n = 3). (C) B16-LS9 cells were seeded at
50 cells/cm2 and treated with 2.5 µM NSC12. After 10 days, cell colonies were stained with crystal violet
and quantified by computerized image analysis. Data are the mean ± SEM of 15 fields for each triplicate
sample. (D) A mechanical wound was performed in a B16-LS9 cell monolayer followed by incubation with
3.0 µM NSC12. After 18 h, cell migration at the leading edge of the wound was quantified by computerized
image analysis. Data are the mean ± SEM of six microscopic fields. (E) B16-LS9-luc cells were injected into
the eye of 48 hpf zebrafish embryos (100 cells/embryo). Then, embryos were incubated with increasing
concentrations of NSC12 at T0. Tumor growth was evaluated 3 days after grafting by measuring the cell
luminescence signal. Data are the mean ± SEM (n = 20). (F) B16-LS9-luc cells were grafted in the liver of
syngeneic mice (50,000 cells/graft). Next, vehicle or NSC12 (7.5 mg/kg) were injected i.p. every other day
and tumor growth was imaged with IVIS Lumina III for the following 14 days. Data are the mean ± SEM
(n = 9). Representative images of control and NSC-12 treated mice imaged 14 days after grafting are shown
on the right. *p < 0.05; **p < 0.01, Student’s t-test (C,D), one-way (E) and two-way (F) analysis of variance.
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To evaluate the effect of NSC12 on the oncogenic potential of B16-LS9 cells, we implemented a
novel orthotopic xenograft assay in which luciferase-transfected cells (B16-LS9-luc cells) were injected
into the eye of zebrafish embryos at 48 hpf. Then, embryos were transferred in fish water in the absence
or in the presence of 5.0 or 10 µM NSC12. NSC12 treatment resulted in a significant inhibition of the
growth of grafted cells when assessed 3 days after injection (Figure 4E). Accordingly, administration of
NSC12 (7.5 mg/kg i.p. every other day) hampered the growth of B16-LS9-luc cells grafted into the liver
of wild-type mice (Figure 4F).
2.4. FGF Trapping Inhibits Human FGF/FGFR Signaling and Proliferation in UM Cells
The capacity of the pan-FGF trap NSC12 to inhibit FGF/FGFR signaling in human UM was
investigated on three cell lines originating from human primary UM lesions (Mel285, Mel270, and 92.1
cells) and one cell line originating from a human UM metastasis (OMM2.3 cells). The major molecular
alterations of these cell lines are summarized in Table 1 (see [33] and references therein).
Table 1. Molecular alterations of the human UM cell lines utilized in this study.
Mel285 92.1 Mel270 OMM2.3
GNAQ (exons 4–5) WT Q209L (626 A > T) Q209P (626 A > C) Q209P (626 A > C)
GNA11 (exons 4–5) Q209L WT WT WT
BAP1 WT WT WT WT
BAP1 Yes, low Yes Yes Yes
SF3B1 WT WT WT WT
EIF1AX WT c.17G/A WT WT







Chr6 Disomy 6p Gain 6p Tetrasomy 6p Tetrasomy 6p





As observed for B16-LS9 cells, NSC12 treatment inhibits the phosphorylation of the FGF receptors
FGFR1 and FGFR3 as well as of their downstream signaling molecules FRS2 and ERK1,2 in the UM
cell lines tested (Figure 5A). This resulted in a significant inhibition of UM cell proliferation/survival
with an IC50 ranging between 6.0 and 8.0 µM NSC12 (Figure 5B). Similar results were obtained after
treatment with the selective tyrosine kinase FGFR inhibitor BGJ398 [34] (data not shown).
In keeping with the hypothesis that the FGF system may play a pivotal role in UM cell survival [9],
NSC12 induced pro-apoptotic caspase-3 activation and PARP cleavage in UM cells (Figure 5C) that
were followed by a significant increase of annexin-V+ apoptotic cells (Figure 5D).
β-catenin signaling has been involved in UM cell migration and metastasis [35–37]. Notably,
NSC12 treatment caused a significant and rapid decrease of the protein levels of β-catenin in UM
cells. (Figure 5E). Accordingly, FGF trapping by NSC12 inhibited cell migration in a Boyden chamber
chemotaxis assay and following the mechanical wound of a UM cell monolayer (Figure 5F,G). It must
be pointed out that both assays were performed under experimental conditions that did not exert a
significant effect on UM cell survival (data not shown).
Together, these findings demonstrate that FGF trapping exerts a significant impact on the autocrine
FGF/FGFR axis in human UM cells.
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Figure 5. Effect of the pan FGF-trap NSC12 on human UM cells. (A) Western blot analysis of the
phosphorylation of FGFR1 and FGFR3 and of the downstream signaling proteins FRS2 and ERK1/2 in
Mel285, 92.1, Mel270, and OMM2.3 cells after 3 h treatment with 15 µM NSC12. (B) Effect of NSC12
treatment on the proliferation of UM cells. Viable cells were counted after 24 h of incubation with
increasing concentrations of NSC12. Data are the mean ± SEM (n = 3). (C) Kinetics of PARP and
caspase-3 cleavage following incubation of MEL285 cells with 15 µM NSC12. (D) Cytofluorimetric
analysis of apoptosis induced in Mel285 cells (upper panels) and 92.1 cells (lower panels) after 12 h
treatment with 15 µM NSC12. (E) Western blot analysis of the levels of β-catenin in Mel285, 92.1,
Mel270, and OMM2.3 cells after 3 h treatment with 15 µM NSC12. (F) Boyden chamber chemotaxis
assay performed on Mel285 cells treated for 4 h with 6.0 µM NSC12. Data are the mean ± SEM of five
fields for each triplicate sample. (G) A mechanical wound was performed in a Mel285 cell monolayer
followed by 18 h incubation with 6.0 µM NSC12. After 18 h, cell migration at the leading edge of
the wound was quantified by computerized image analysis. Representative images of untreated and
NSC12-treated cells are shown on the right (black lines highlight the front of cell migration). Data are
the mean ± SEM of 6 microscopic fields. In (A,C,D) the right panel shows the densitometric analysis of
immunoreactive bands normalized to GAPDH protein levels. ** p < 0.01, Student’s t test.
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3. Discussion
In the present work, we demonstrate that different FGF trapping approaches inhibit the tumorigenic
and metastatic activity of hepatotropic murine B16-LS9 cells and hamper the proliferation, survival,
and migration of primary and metastatic human UM cell lines.
B16-LS9 cells are a murine cell line originated from a B16-F1 liver metastasis and characterized by
a unique tropism for the hepatic tissue that recapitulates the metastatic growth patterns observed in the
human disease [25]. Indeed, despite its cutaneous origin, B16-LS9 cells have been selectively developed
after serial passages for liver specific metastasis, leading to the only model metastasizing to the liver
following intraocular injection in syngeneic animals [38]. Thus, B16-LS9 cells have been utilized
as an experimental model to investigate the mechanisms responsible for UM liver tropism [26–28],
drug testing for UM therapy [29–31], immunologic and angiogenic aspects of UM and imaging
methodologies (see [38] and references therein).
Here, we show that B16-LS9 cells express different FGFRs and the prototypic FGFR ligand FGF2.
This leads to the constitutive phosphorylation of FGFR1 and FGFR3, as well as of the downstream
signaling proteins FRS2, ERK1/2, and AKT. As observed for different FGF-dependent tumor cell types,
this activates an autocrine loop of stimulation in B16-LS9 cells, which is inhibited by the overexpression
of the natural extracellular FGF trap PTX3 [16,17,21,39]. The capacity of PTX3 to suppress the
proliferative and migratory activity of B16-LS9 transfectants highlights the non-redundant role of the
autocrine FGF/FGFR system in the tumorigenic activity of these cells [12]. Indeed, PTX3-overexpressing
B16-LS9 tumor grafts showed a reduced rate of growth in syngeneic mice and a reduced metastatic
activity when injected in the blood stream of zebrafish embryos.
To assess the effect of the systemic delivery and stromal accumulation of PTX3 protein on UM
growth, we took advantage of TgN (Tie2-hPTX3) mice, a transgenic mouse line we generated in
the C57BL/6 background that expresses PTX3 under the control of the endothelial specific Tie2/Tek
transcription regulatory sequences [21]. When injected s.c. in TgN (Tie2-hPTX3) mice, B16-LS9 cells
showed a reduced rate of growth, thus confirming the oncosuppressive effect exerted by PTX3 on
these cells. Notably, the systemic accumulation of PTX3 protein resulted also in a significant inhibition
of the capacity of B16-LS9 cells to originate liver metastases when injected into the spleen of the
transgenic animals. Even though we cannot rule out the possibility that PTX3 may have multiple
impacts on tumor growth, the data support the notion that the anti-tumor effects of PTX3 are related to
its inhibitory action on the autocrine/paracrine loops of stimulation triggered by the FGF/FGFR system
in FGF-dependent B16-LS9 cells.
Despite its oncosuppressive effects, the complex proteinaceous structure of PTX3 hampers its
pharmacological exploitation. For this reason, the scaling down of this macromolecule to PTX3-derived
small molecules was attempted to take advantage of its antitumor properties in a translational outlook.
This led to the identification of the small molecule NSC12 as the first orally available pan-FGF trap
endowed with a potent anti-tumor activity in different FGF-dependent tumor models (reviewed
in [7]). On this basis, a series of experiments were performed to assess the effect of NSC12 on B16-LS9
cells. In keeping with its FGF trapping activity, NSC12 inhibits FGFR phosphorylation, proliferation,
and migration of B16-LS9 cells. Notably, NSC12 was able to suppress the growth of these cells also
when orthotopically implanted in the eye of zebrafish embryos or when injected into the liver of
syngeneic mice.
Even though the syngeneic B16-LS9 model shows significant experimental advantages and
resemblance to UM behavior concerning its hepatotropic features, significant genetic differences occur
between cutaneous and UM [40,41]. This prompted us to assess the impact of the FGF trapping activity
of NSC12 on both primary and metastatic human UM cell lines. Notably, NSC12 treatment was able to
inhibit FGFR activation and downstream signaling in all the cell lines tested. This was paralleled by
the activation of the pro-apoptotic proteins PARP and caspase-3, thus leading to UM cell death.
The β-catenin signaling pathway has been involved in the growth, migratory, and invasive
behavior of UM cells [35]. Indeed, β-catenin immunoreactivity is increased in primary UM and
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is associated with a shorter patient survival [36], its expression representing a biomarker potently
correlated to metastatic UM [37]. The FGF/FGFR axis has been shown to stabilize β-catenin, leading to
its nuclear accumulation and activation of the β-catenin signaling pathway [42,43]. Notably, our data
demonstrate that NSC12 induces a decrease of β-catenin levels in UM cells that was paralleled by a
significant inhibition of UM cell migration in a Boyden chamber assay or following the mechanical
wound of the cell monolayer. Further studies will be required to dissect the impact of β-catenin
downregulation induced by FGF inhibitors on the tumorigenic and metastatic behavior of UM cells.
In keeping with our preclinical observations, the analysis of the publicly available mRNA profiling
dataset of 80 primary human UM specimens present in TCGA indicates that the upregulation of
different members of the FGF or FGFR families are associated with poorer prognosis, chromosome 3
monosomy, and BAP1 mutation. These data further support the hypothesis that the FGF/FGFR system
plays a non-redundant role in UM. Several experimental evidences reinforce this assumption. Similar
to NSC12, neutralizing antibodies and an antisense oligonucleotide directed against FGF2 have been
shown to reduce cell proliferation and survival in various human UM cell lines [12]. When examined
on an array of 32 human UM samples, FGF2 immunoreactivity was detectable in more than 50% of
cases, its frequency being higher in mixed/epithelioid samples than in spindle cell type specimens [13].
Notably, immunohistochemical staining revealed an elevated FGF2 expression in UM metastases
when compared to primary lesions, further implying FGF2 in UM progression [13]. In addition,
the production of FGF2 by UM cells and primary tumors may contribute, together with vascular
endothelial growth factor, to the angiogenic activity of UM that, in turn, favors its hematogenous
metastatic spread [10,11]. Finally, recent observations have shown that FGF2 produced by hepatic
stellate cells confers resistance of metastatic UM cells to bromodomain and extraterminal protein
inhibitors and to the histone deacetylase inhibitor vorinostat via FGFR activation [44]. Together with
our observations, these data suggest that drugs targeting the FGF/FGFR system might be considered
for an adjuvant chemotherapy treatment of metastatic UM.
Thus far, different approaches have been developed to target the FGF/FGFR system [9] and various
FGF/FGFR inhibitors are under evaluation in clinical trials on cancer patients affected by different
kinds of tumors [8]. In this frame, drugs targeting FGF ligands may represent an interesting alternative
to tyrosine kinase FGFR inhibitors. To this respect, the small molecule NSC12 is the first orally active
multi-FGF trap. Of note, in keeping with the lack of pathological consequences following constitutive
PTX3 overexpression in transgenic mice, the anti-tumor action of NSC12 occurs in the absence of any
significant effect on body weight and survival of treated animals [21]. Thus, NSC12 may represent a
lead compound for the development of orally active small molecule therapeutics for the treatment of
UM in which the ligand-dependent activation of the FGFR pathway is an oncogenic driver. Further
experiments aimed to assess the in vivo efficacy of this FGF trapping approach in orthotopic and liver
metastatic models of human UM are required to confirm this hypothesis.
4. Materials and Methods
4.1. Reagents
All reagents were of analytical grade. Dulbecco’s modified Eagle medium (DMEM),
RPMI 1640 medium and fetal bovine serum (FBS) were from GIBCO Life Technologies (Grand
Island, NY, USA). Penicillin, streptomycin, Triton-X100, BriJ, sodium orthovanadate, protease
inhibitor cocktail, and anti-α-tubulin were from Sigma-Aldrich (St. Louis, MO, USA). Bradford
reagent was from Bio-Rad Laboratories (Milan, Italy). Trizol, MMLV reverse transcriptase and
CellTracker Red CMTPX Dye were from Invitrogen (Carlsbad, CA, USA). PVP-free polycarbonate
filters were obtained from Costar (Cambridge, MA, USA). Diff-Quik reagent was obtained
from Dade-Behring (Deer eld, IL, USA). ONE-Glo™ Reagent and DNAse were from Promega
(Milan, Italy). Recombinant FGF2 was purchased from Tecnogen (Caserta, Italy). Anti-FGFR1,
anti-ERK1/2, anti-phospho-ERK1/2 (Thr202/Tyr204), anti-phospho-AKT (Ser473), anti-cleaved-PARP,
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anti-cleaved-caspase-3, and anti-β-catenin were from Cell Signaling Technologies (Danver, MA, USA).
Anti-phospho-FGFR1 (Tyr766), anti-phospho-FRS2 (Tyr196), anti-FGFR3, and anti-GAPDH were from
Santa Cruz (Santa Cruz, CA, USA). Anti-phospho-FGFR3 (Tyr724) was from ABCAM (Cambridge,
UK). Matrigel was from Cultrex BME (Gaithersburd, MD, USA). Floseal hemostatic matrix was from
Baxter (Deerfield, IL, USA).
4.2. Cell Cultures
Murine B16-LS9 cells [25] were maintained in DMEM supplemented with 10% FBS, 100 U/mL
penicillin, and 100 µg/mL streptomycin. B16-LS9 cells were transfected with a pBABE/Puro vector
harboring the full-length human PTX3 cDNA or with empty vector as described [19]. Stable hPTX3_LS9
and mock_LS9 cell populations were generated by puromycin selection. Luciferase-transfected B16-LS9
cells (B16-LS9-luc cells) were generated as described [21]. Human UM cells [45–47] were maintained in
RPMI 1640 medium supplemented with 10% (Mel285, 92.1, and OMM2.3 cells) or 20% FBS (Mel270
cells), 100 U/mL penicillin, and 100 µg/mL streptomycin.
4.3. Real-Time PCR Analysis
For mRNA expression analysis, cells were processed, and total RNA was extracted using TRIzol
Reagent according to manufacturer’s instructions. Contaminating DNA was digested using DNAse
and 2.0 µg of total RNA were retro-transcribed with MMLV reverse transcriptase using random
hexaprimers in a final 20 µL volume. Then, 1/10th of the reaction was analyzed by semiquantitative
RT-PCR using specific primers (Table 2). The PCR products were then electrophoresed on a 1.5%
agarose gel and visualized by ethidium bromide staining.









4.4. Western Blot Analysis
For the analysis of FGF signaling, cell samples were homogenized in RIPA buffer containing
1.0% Triton-X100, 0.2% BriJ, 1.0 mM sodium orthovanadate, and protease inhibitor cocktail. Protein
concentrations were determined using the Bradford protein assay. Western blot analysis was performed
using rabbit anti-FGFR1, anti-pFGFR1, anti-FGFR3, anti-pFGFR3, anti-pFRS2, anti-pAKT, anti-ERK1/2,
anti-pERK1/2, anti-cleaved-PARP, anti-cleaved-caspase-3, anti-β-catenin antibodies, and normalized
with anti-α-tubulin or anti-GAPDH antibodies. Densitometric analysis was performed using the
Bio-Rad Image Lab Software 5.2.1. The whole blot showing all the bands with all molecular weight
markers on the Western are included in the Supplementary Materials.
4.5. Cell Proliferation Assay
Cells were seeded on 48-well plates at 1 × 104 cells/cm2 (B16-LS9 cells) or at 1.5 × 104 cells/cm2
(Mel285, Mel270, 92.1, and OMM2.3 cells). After 24 h, cells were treated with increasing concentrations
of NSC12. After a further 24 or 48 h incubation, cells were trypsinized and viable cell counting was
performed with the MACSQuant® Analyzer (Miltenyi Biotec) as reported [48].
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4.6. Colony Formation Assay
B16-LS9 cells were seeded in 35-mm culture dishes at 50 cells/cm2. After 10 days of incubation,
cell colonies were stained with crystal violet and quantified by computerized image analysis.
4.7. Chemotaxis Assay
Mel285 cells were seeded at 1.0 × 106 cells/mL in the upper compartment of a Boyden chamber
containing gelatin-coated PVP-free polycarbonate filters (8 µm pore size). RPMI medium supplemented
with 1.0% FBS was placed in the lower compartment in the absence or in the presence of 6.0 µM NSC12.
After 4 h of incubation at 37 ◦C, cells that migrated to the lower side of the filter were stained with
Di-Quik reagent. Five random fields were counted for each triplicate sample.
4.8. Wound Healing Assay
Confluent B16-LS9 or Mel285 cells were scraped with a 200 µL tip to obtain a mechanical wound
through the cell monolayer. Then, B16-LS9 cells were maintained in DMEM supplemented with
0.4% FBS in the absence or in the presence of 3.0 µM NSC12 whereas Mel285 cells were maintained
in RPMI medium supplemented with 1.0% FBS and treated or not with 6.0 µM NSC12. After 18 h,
cells at the leading edge of the wound were photographed under an inverted Zeiss Axiovert 200 M
photomicroscope and cell migration wound was quantified by computerized image analysis.
4.9. Apoptotic Cell Death Analysis
Mel285 or 92.1 cells were seeded at 2.5 × 105 cells/mL in the absence or in the presence of
15 µM NSC12. After 12 h, apoptotic cell death was assessed by cytofluorimetric analysis following
Annexin-V/propidium iodide-double staining according to manufacturer’s instructions.
4.10. Tumor Graft and Liver Metastasis Assays in Mice
Animal studies were approved by the local animal ethics committee (OPBA, Organismo Preposto
al Benessere degli Animali, Università degli Studi di Brescia, Italy) and by the Italian Ministero della
Salute (Project: Integrated model for the study and therapy of uveal melanoma; authorization no.
1306/2015-PR). All the procedures and animal care were conformed to institutional guidelines that
comply with national and international laws and policies (EEC Council Directive 86/609, OJ L 358, 12
December 1987).
C57BL/6 (Charles River, Calco, Italy) and transgenic TgN (Tie2-hPTX3) mice [21] were maintained
under standard housing conditions.
B16-LS9 cells were injected s.c. or into the spleen [28] of wild-type and TgN (Tie2-hPTX3) mice
at 50,000 and 20,000 cells/graft, respectively. Subcutaneous tumors were measured with calipers and
tumor volume was calculated according to the formula V = (D × d2)/2, where D and d are the major and
minor perpendicular tumor diameters, respectively. Liver metastases were counted under a dissecting
microscope 14 days after cell injection.
As for liver tumor grafts, 20 µL of a cell suspension containing 50,000 B16-LS9-luc cells in Matrigel
(1:1, vol/vol) were injected into the liver of wild-type mice. To minimize bleeding and to avoid leakage
of tumor cells after needle removal, Floseal hemostatic matrix was applied on the liver surface at the
site of injection. NSC12 treatment (7.5 mg/kg) was performed every other day by i.p. injection in a 100
µL final volume. Tumor growth was imaged with IVIS Lumina III during the following 14 days.
4.11. Zebrafish Embryo Assays
The AB zebrafish line was maintained at 28 ◦C on a 14 h light/10 h dark cycle. After spawning,
fertilized eggs were harvested and incubated in fish water at 28 ◦C. Zebrafish embryos were staged
and maintained in 0.003% 1-phenyl-2-thiourea (Sigma) starting from 24 hpf to prevent pigmentation.
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For the metastasis assay, B16-F10 cells were stained with the red fluorescent CellTracker Red
CMTPX Dye. Then, 80–100 cells/embryo were injected into the blood circulation in the ventral
region of the duct of Cuvier of zebrafish embryos at 48 hpf. During the next 3 days, the growth of
fluorescent metastases in the tail vascular plexus was quantified by fluorescence microscopy followed
by computerized image analysis of the fluorescent tumor area [32].
For the orthotopic UM model, B16-LS9-luc cells (100 cells/embryo) were injected into the eye
of zebrafish embryos at 48 hpf using a borosilicate needle and an Eppendorf FemtoJet microinjetor
equipped with an InjectMan NI2 manipulator. Then, embryos were transferred in fish water in the
absence or in the presence of increasing concentrations of NSC12. Tumor growth was evaluated 3 days
after grafting by measuring the cell luminescence signal as it follows: embryos were anesthetized and
singularly placed in a well of a white polystyrene 96-well plate; medium was removed and replaced
with 50 µL of RIPA buffer plus 50 µL of ONE-Glo™ Reagent; finally, luminescence was measured using
an EnSight multimode plate reader (Perkin Elmer, Waltham, MA, USA).
4.12. Statistical Analysis
Statistical analysis was performed with GraphPad Prism 7 (San Diego, CA, USA) using Student’s
t-test or one-way analysis of variance followed by Bonferroni multiple comparison post-test. Tumor
growth data were analyzed by two-way analysis of variance, followed by Bonferroni post-test.
Differences were considered significant when p values < 0.05.
5. Conclusions
We demonstrate that the natural extracellular FGF trap PTX3 inhibits the oncogenic activity of
hepatotropic murine melanoma B16-LS9 cells. Translational exploitation of these findings shows
that the PTX3-derived pan-FGF trap small molecule NSC12 hampers the tumorigenic and liver
metastatic activity of B16-LS9 cells and affects autocrine FGF/FGFR signaling, proliferation, survival,
and migration of human UM cells. Together, these findings indicate that FGF trapping may represent a
novel therapeutic strategy for the treatment of metastatic UM.
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6694/11/9/1305/s1,
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